Macromolecular Antibody Drugs

Promoting Bone Healing

NGF promotes osteogenesis and angiogenesis, improves the bone microenvironment, and supports fracture repair.

T

Targeted Pain Relief

Inhibiting NGF signaling alleviates inflammatory and neuropathic pain, offering potential for effective pain management.

Canine PD-1 Therapy

PD-1 monoclonal antibodies targeting canine tumors have demonstrated promising therapeutic effects in clinical trials.

AC003

Nerve Growth Factor (NGF) is a key mediator of pain perception. Besides its expression in the nervous system, it is also found in bone tissue and participates in bone growth, development, and repair.

Studies in animal bone injury models have shown that NGF has significant therapeutic effects, promoting the differentiation and proliferation of osteoblasts, stimulating angiogenesis, improving the bone microenvironment, and thereby facilitating the healing of fractures and bone defects. Since NGF is also involved in pain signal transmission, drugs targeting NGF have the potential to treat pain.

NGF antibody drugs can alleviate NGF-mediated pain and inflammation, such as pain caused by skeletal diseases like osteoarthritis, as well as neuropathic pain, by inhibiting the NGF signaling pathway.

AC003

Promoting Bone Repair

NGF stimulates osteoblasts and angiogenesis, improves the bone microenvironment, and accelerates healing of fractures and defects.

Precision Pain Control

Inhibiting NGF signaling reduces pain caused by inflammation or skeletal disorders, enhancing animal comfort.

f

Modulating the Bone Microenvironment

PD-1 monoclonal antibodies targeting canine tumors have shown promising therapeutic effects in clinical trials.

AC004

Canine tumors have become common clinical diseases. Monoclonal antibodies targeting Programmed Cell Death 1 (PD-1) are among the most promising treatments for human cancers. Canine PD-1 antibodies used in clinical trials have also demonstrated efficacy in treating canine cancers.

Key Breakthrough in Canine Tumor Immunotherapy

Canine tumors are a common clinical issue. Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) have significantly improved immune response and therapeutic outcomes in human oncology.

Clinical Prospects of PD-1 Targeted Antibodies

PD-1 antibodies for canines have demonstrated therapeutic potential in clinical trials, showing promising efficacy and warranting further development and application.

AC004

Contact Us

ir.marking@amicurebios.com

Room 1811, 18th Floor Hopewell Centre 23 Harbour Road, Wan Chai Hong Kong

Where Innovation Meets

Accelerating the Future of Pet Health Together

Partnership